8-KEarnings & ResultsExhibits & Filings

BOSTON SCIENTIFIC CORP 8-K Report, Financial Results (Jul 27, 2023)

Filed July 27, 2023For Securities:BSX

Summary

Boston Scientific Corporation (BSX) filed an 8-K on July 27, 2023, primarily to furnish its press release detailing financial results for the second quarter ended June 30, 2023. While the 8-K itself does not contain the detailed financial data, it directs investors to the accompanying press release (Exhibit 99.1) for these crucial operational and financial updates. This filing is standard practice for earnings announcements and serves as the official notification of the Q2 2023 performance. Investors should carefully review the furnished press release for specific figures regarding revenue, profitability, segment performance, and any forward-looking guidance provided by the company. The information presented in the press release is key to understanding BSX's recent performance, its position within the medical device market, and its future outlook. The filing explicitly states that this information is furnished and not deemed "filed" for purposes of certain securities regulations, a standard disclaimer for such announcements.

Key Highlights

  • 1Boston Scientific furnished its Q2 2023 earnings press release as part of an 8-K filing on July 27, 2023.
  • 2The filing directs investors to Exhibit 99.1 for detailed financial results and operational commentary for the second quarter ended June 30, 2023.
  • 3This 8-K filing is a standard regulatory step to announce and provide access to the company's latest financial performance.
  • 4The press release contains the most critical information regarding revenue, earnings, and business segment performance.
  • 5Information furnished in this 8-K is not deemed 'filed' under Section 18 of the Exchange Act, a typical disclaimer.

Frequently Asked Questions

Boston Scientific's Q2 2023 financial results are detailed in the press release furnished as Exhibit 99.1 to their 8-K filing dated July 27, 2023.

This 8-K filing is significant because it officially announces and provides access to Boston Scientific's financial performance for the second quarter of 2023 through an accompanying press release, which is crucial for understanding the company's operational health and market position.

No, the 8-K filing itself primarily serves to furnish the press release (Exhibit 99.1) which contains the detailed financial results and commentary for Q2 2023. Investors should refer to the press release for specific figures.

The filing states that the information contained in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section.